| Literature DB >> 26687144 |
Moniek Riemersma1, D Sean Froese2, Walinka van Tol3, Udo F Engelke4, Jolanta Kopec2, Monique van Scherpenzeel3, Angel Ashikov3, Tobias Krojer2, Frank von Delft2, Marco Tessari5, Anna Buczkowska6, Ewa Swiezewska6, Lucas T Jae7, Thijn R Brummelkamp7, Hiroshi Manya8, Tamao Endo8, Hans van Bokhoven9, Wyatt W Yue10, Dirk J Lefeber11.
Abstract
A unique, unsolved O-mannosyl glycan on α-dystroglycan is essential for its interaction with protein ligands in the extracellular matrix. Defective O-mannosylation leads to a group of muscular dystrophies, called dystroglycanopathies. Mutations in isoprenoid synthase domain containing (ISPD) represent the second most common cause of these disorders, however, its molecular function remains uncharacterized. The human ISPD (hISPD) crystal structure showed a canonical N-terminal cytidyltransferase domain linked to a C-terminal domain that is absent in cytidyltransferase homologs. Functional studies demonstrated cytosolic localization of hISPD, and cytidyltransferase activity toward pentose phosphates, including ribulose 5-phosphate, ribose 5-phosphate, and ribitol 5-phosphate. Identity of the CDP sugars was confirmed by liquid chromatography quadrupole time-of-flight mass spectrometry and two-dimensional nuclear magnetic resonance spectroscopy. Our combined results indicate that hISPD is a cytidyltransferase, suggesting the presence of a novel human nucleotide sugar essential for functional α-dystroglycan O-mannosylation in muscle and brain. Thereby, ISPD deficiency can be added to the growing list of tertiary dystroglycanopathies.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26687144 DOI: 10.1016/j.chembiol.2015.10.014
Source DB: PubMed Journal: Chem Biol ISSN: 1074-5521